

# Byoung Chul Cho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5058622/publications.pdf>

Version: 2024-02-01

340  
papers

26,028  
citations

16791

66  
h-index

9605

147  
g-index

345  
all docs

345  
docs citations

345  
times ranked

22483  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Na <sup>+</sup> ve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. <i>Cancer Research and Treatment</i> , 2023, 55, 83-93.	1.3	2
2	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1093-1101.	2.0	23
3	Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2022, 28, 1117-1126.	3.2	52
4	Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC. <i>Cancer Discovery</i> , 2022, 12, 16-19.	7.7	7
5	Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2022, 82, 18-20.	0.4	5
6	Predicting treatment outcomes using <sup>18</sup> F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	1.4	7
7	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
8	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	3.2	74
9	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	0.5	43
10	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210791.	1.4	10
11	MARIPOSA: phase 3 study of first-line amivantamab+azertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 639-647.	1.1	44
12	Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 718-723.	0.5	29
13	The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges. <i>Frontiers in Oncology</i> , 2022, 12, 811247.	1.3	17
14	Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. <i>Current Oncology</i> , 2022, 29, 2154-2164.	0.9	16
15	Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). <i>Clinical Cancer Research</i> , 2022, 28, 3277-3286.	3.2	27
16	SKI-INHIBITOR, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. <i>Clinical and Translational Immunology</i> , 2022, 11, e1364.	1.7	6
17	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100332.	0.6	15
18	Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 781-792.	5.1	150

#	ARTICLE	IF	CITATIONS
19	A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2022, 31, 747-757.	1.9	6
20	Abstract 5481: Combination therapy with anti-PD-1 and YH29407, a novel IDO1 inhibitor, enhances T cell-mediated antitumor immunity in MC38 tumor-bearing mice. Cancer Research, 2022, 82, 5481-5481.	0.4	0
21	AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with <i>RET</i> fusionâ€“positive advanced/metastatic NSCLC.. Journal of Clinical Oncology, 2022, 40, TPS9159-TPS9159.	0.8	0
22	Abstract 3527: Novel bacteria strains, CJRS-10671 and CJRS-10672, enhance anti-tumor efficacy in LLC1 syngeneic model and humanized PDX mice model. Cancer Research, 2022, 82, 3527-3527.	0.4	0
23	Abstract CT198: Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study. Cancer Research, 2022, 82, CT198-CT198.	0.4	3
24	Amivantamab and lazertinib in patients with EGFR-mutant nonâ€“small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.. Journal of Clinical Oncology, 2022, 40, 9006-9006.	0.8	34
25	Abstract LB515A: A MET targeting biparatopic antibody-drug conjugates (ADC), REGN5093-M114, has an antitumor efficacy in NSCLC harboring MET gene alterations. Cancer Research, 2022, 82, LB515A-LB515A.	0.4	1
26	Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. Cancer Research, 2022, 82, CT561-CT561.	0.4	0
27	Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs. Cancer Research, 2022, 82, LB544-LB544.	0.4	0
28	Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study. Cancer Research, 2022, 82, LB078-LB078.	0.4	4
29	Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, <i>EGFR</i>-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9013-9013.	0.8	14
30	Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous nonâ€“small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).. Journal of Clinical Oncology, 2022, 40, 9039-9039.	0.8	9
31	Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.. Journal of Clinical Oncology, 2022, 40, 8541-8541.	0.8	11
32	Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.. Journal of Clinical Oncology, 2022, 40, 6072-6072.	0.8	1
33	Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Annals of Oncology, 2021, 32, 395-403.	0.6	53
34	Olmutinib in T790Mâ€“positive nonâ€“small cell lung cancer after failure of firstâ€“line epidermal growth factor receptorâ€“tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer, 2021, 127, 1407-1416.	2.0	17
35	Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.. Journal of Clinical Oncology, 2021, 39, 168-168.	0.8	5
36	Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.. Journal of Clinical Oncology, 2021, 39, 204-204.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	0.8	74
38	KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. <i>Future Oncology</i> , 2021, 17, 1143-1153.	1.1	63
39	DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway. <i>Experimental and Molecular Medicine</i> , 2021, 53, 643-653.	3.2	6
40	Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 7435.	1.6	2
41	Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 709-711.	0.5	2
42	Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8580-TPS8580.	0.8	1
43	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN). <i>Journal of Clinical Oncology</i> , 2021, 39, 6020-6020.	0.8	4
44	Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3150-TPS3150.	0.8	2
45	CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9132-TPS9132.	0.8	12
46	Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. <i>Journal of Clinical Oncology</i> , 2021, 39, 9006-9006.	0.8	55
47	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 3096.	1.7	7
48	Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	3.2	64
49	Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100180.	0.6	3
50	Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4397-4409.	3.2	49
51	Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). <i>Clinical Lung Cancer</i> , 2021, 22, 601-606.	1.1	31
52	Abstract 1787: YH29407, a novel IDO1 inhibitor, enhances the anti-tumor effects through increased tumor-reactive T cell functions in solid tumor. , 2021, , .		0
53	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). <i>Clinical Lung Cancer</i> , 2021, 22, 301-312.e8.	1.1	10
54	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	5.1	222

#	ARTICLE	IF	CITATIONS
55	Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust <i>in vivo</i> antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC). <i>Cancer Research</i> , 2021, 81, 1467-1467.	0.4	12
56	Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study. <i>Cancers</i> , 2021, 13, 3681.	1.7	3
57	Abstract CT255: Canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer: CANOPY-A trial. , 2021, , .		0
58	Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D. , 2021, , .		0
59	Abstract 1106: BRAF and EGFR fusion as a novel mechanism of resistance mechanism to Lazertinib, 3rd-generation EGFR-TKI, in EGFR-mutant NSCLC. <i>Cancer Research</i> , 2021, 81, 1106-1106.	0.4	2
60	Amivantamab in EGFR Exon 20 Insertion-“Mutated Non-“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	0.8	320
61	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2021, 398, 759-771.	6.3	642
62	Clinical decision support algorithm based on machine learning to assess the clinical response to anti-“programmed death-1 therapy in patients with non-“small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 153, 179-189.	1.3	16
63	Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-“SCLC: Results From the Phase 3 MERU Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1570-1581.	0.5	65
64	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100224.	0.6	6
65	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 7012-7020.	1.3	8
66	The promise of bispecific antibodies: Clinical applications and challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102240.	3.4	28
67	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100206.	0.6	3
68	Anti-“cytotoxic T-lymphocyte-“associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 162-170.	0.9	6
69	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1547-1558.	0.5	108
70	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-“Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1718-1732.	0.5	141
71	470-“A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59). , 2021, 9, A499-A499.		4
72	Abstract P02-01: Repotrectinib in patients with <i>in</i> NTRK <i>in</i> fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, P02-01-P02-01.	1.9	5

#	ARTICLE	IF	CITATIONS
73	Real-world use of osimertinib in non-“small cell lung cancer: ASTRIS study Korean subgroup analysis. <i>Current Medical Research and Opinion</i> , 2020, 36, 477-482.	0.9	9
74	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-“Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 288-293.	0.5	328
75	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 125, 49-57.	1.3	45
76	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-“2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	5.1	303
77	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-“Positive Non-“Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 538-547.	0.8	221
78	Overall Survival with Osimertinib in Untreated, <i>EGFR</i>-Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020, 382, 41-50.	13.9	1,725
79	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 4521-4531.	2.0	10
80	Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in <i>ALK</i>-positive non-small-cell lung cancer. , 2020, 8, e000970.		16
81	Mouse-“human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. <i>British Journal of Cancer</i> , 2020, 123, 1720-1729.	2.9	18
82	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1550-1563.	3.2	99
83	Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2298-2307.	1.9	30
84	Bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
85	The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2020, 12, 6426-6434.	0.6	30
86	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-“MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion-“Driven NSCLC. <i>Cancer Discovery</i> , 2020, 10, 1194-1209.	7.7	158
87	Tepotinib in Non-“Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	13.9	500
88	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 9050.	1.6	43
89	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-Î² and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119
90	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. <i>British Journal of Cancer</i> , 2020, 122, 1649-1660.	2.9	17

#	ARTICLE	IF	CITATIONS
91	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
92	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 2020, 38, 1580-1590.	0.8	189
93	Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Clinical Lung Cancer, 2020, 21, e84-e88.	1.1	35
94	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncology, The, 2020, 21, 373-386.	5.1	300
95	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 661.	3.4	446
96	Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma. BMC Cancer, 2020, 20, 348.	1.1	13
97	Establishment and characterization of patient-derived xenografts as preclinical models for head and neck cancer. BMC Cancer, 2020, 20, 316.	1.1	14
98	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3287-3295.	3.2	66
99	Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade. JCI Insight, 2020, 5, .	2.3	27
100	Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, 3584-3584.	0.8	14
101	Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (<i>NTRK</i>-fp) solid tumors: An updated integrated analysis.. Journal of Clinical Oncology, 2020, 38, 3605-3605.	0.8	33
102	Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. Journal of Clinical Oncology, 2020, 38, 9503-9503.	0.8	179
103	Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).. Journal of Clinical Oncology, 2020, 38, 9505-9505.	0.8	24
104	Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9512-9512.	0.8	54
105	Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9515-9515.	0.8	57
106	Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.. Journal of Clinical Oncology, 2020, 38, 9516-9516.	0.8	17
107	Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.. Journal of Clinical Oncology, 2020, 38, 9556-9556.	0.8	3
108	Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9558-9558.	0.8	7

#	ARTICLE	IF	CITATIONS
109	ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2020, 38, 9601-9601.	0.8	1
110	Dynamic changes in circulating PD-1 <sup>+</sup> CD8 <sup>+</sup> T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e21690-e21690.	0.8	1
111	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9075-TPS9075.	0.8	6
112	TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring <i>ROS1</i> or <i>NTRK1-3</i> rearrangements.. Journal of Clinical Oncology, 2020, 38, TPS9637-TPS9637.	0.8	8
113	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Research and Treatment, 2020, 52, 284-291.	1.3	4
114	Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Cancer Research and Treatment, 2020, 52, 1112-1119.	1.3	10
115	Contemporary management and associated outcomes of 3,151 patients with stage III non-small cell lung cancer (NSCLC) in a real-world setting: Results of KINDLE, a multicountry observational study.. Journal of Clinical Oncology, 2020, 38, 9043-9043.	0.8	1
116	Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) patients from East Asia.. Journal of Clinical Oncology, 2020, 38, e21608-e21608.	0.8	0
117	Tepotinib in patients (pts) with NSCLC with <i>MET</i> exon 14 ( <i>MET</i> ex14) skipping: Health-related quality of life (HRQoL).. Journal of Clinical Oncology, 2020, 38, 9575-9575.	0.8	1
118	281â€¦JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC). , 2020, , .		2
119	572â€¦Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkineâ„¢ potentiates anti-cancer effects in preclinical cancer models. , 2020, , .		0
120	Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity. Head and Neck, 2019, 41, 198-207.	0.9	18
121	Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2019, 20, 1454-1466.	5.1	125
122	Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. Lung Cancer, 2019, 136, 30-36.	0.9	32
123	ASTRIS: a global real-world study of osimertinib in >3000 patients with <i>EGFR</i> T790M positive non-small-cell lung cancer. Future Oncology, 2019, 15, 3003-3014.	1.1	42
124	NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 11231.	1.6	4
125	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer, 2019, 135, 66-72.	0.9	22
126	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. Cancer Chemotherapy and Pharmacology, 2019, 84, 405-414.	1.1	5



#	ARTICLE	IF	CITATIONS
127	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1&sup2; study. <i>Lancet Oncology</i> , The, 2019, 20, 1681-1690.	5.1	92
128	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1670-1680.	5.1	125
129	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1506-1517.	5.1	767
130	Identification of TRE&sup1;30 as Reversible Inhibitor of Pan&sup;EGFR Mutants while Sparing EGFR Wild&sup;Type Activity. <i>Bulletin of the Korean Chemical Society</i> , 2019, 40, 1222-1225.	1.0	1
131	Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node Metastasis. <i>Anticancer Research</i> , 2019, 39, 6307-6316.	0.5	13
132	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK &sup;rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10581.	3.3	40
133	Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1065-1073.	0.4	79
134	Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer. <i>Cancer Letters</i> , 2019, 466, 23-34.	3.2	23
135	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non&sup;Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2575-2587.	3.2	71
136	Real-World Analysis of the Efficacy of Rebiopsy and <i>EGFR</i> Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2019, 60, 525.	0.9	23
137	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. <i>Lung Cancer</i> , 2019, 134, 46-51.	0.9	24
138	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib&sup;Untreated ALK-Positive Advanced Non&sup;Small Cell&sup;Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1233-1243.	0.5	324
139	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)&sup;Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1255-1265.	0.5	59
140	Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate. <i>PLoS ONE</i> , 2019, 14, e0214291.	1.1	2
141	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1613-1623.	1.2	66
142	Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study. <i>Anticancer Research</i> , 2019, 39, 1403-1409.	0.5	10
143	Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 131, 139-146.	0.9	25
144	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	6.3	2,347

#	ARTICLE	IF	CITATIONS
145	KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. <i>Future Oncology</i> , 2019, 15, 1057-1066.	1.1	132
146	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1095-1102.	1.9	37
147	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 19909.	1.6	18
148	Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. <i>PLoS ONE</i> , 2019, 14, e0224379.	1.1	12
149	Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. , 2019, 7, 339.		65
150	High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 20197.	1.6	15
151	Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e123-e132.	1.1	53
152	A Phase I/IIb Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	7.7	88
153	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. <i>Journal of Thoracic Oncology</i> , 2019, 14, 99-106.	0.5	82
154	The Ratio of Peripheral Regulatory T Cells to Lox-1 <sup>+</sup> Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 243-246.	2.5	85
155	Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. <i>Lung Cancer</i> , 2019, 127, 112-121.	0.9	31
156	Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2558-2558.	0.8	1
157	Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3017-3017.	0.8	25
158	A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4027-4027.	0.8	28
159	Three-year overall survival update from the PACIFIC trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8526-8526.	0.8	29
160	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9009-9009.	0.8	74
161	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 <sup>+</sup> fusion-positive non-small cell lung cancer (TRIDENT-1 study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9011-9011.	0.8	58
162	Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9016-9016.	0.8	20

#	ARTICLE	IF	CITATIONS
163	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.. Journal of Clinical Oncology, 2019, 37, 9020-9020.	0.8	39
164	Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology, 2019, 37, 9048-9048.	0.8	2
165	First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.. Journal of Clinical Oncology, 2019, 37, 9054-9054.	0.8	3
166	Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.. Journal of Clinical Oncology, 2019, 37, e20661-e20661.	0.8	5
167	CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS8570-TPS8570.	0.8	6
168	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS9124-TPS9124.	0.8	11
169	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. Cancer Research and Treatment, 2019, 51, 300-312.	1.3	48
170	Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection. Cancer Research and Treatment, 2019, 51, 1052-1063.	1.3	9
171	Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types.. Journal of Clinical Oncology, 2019, 37, 3046-3046.	0.8	0
172	Lazertinib, a 3 <sup>rd</sup> generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.. Journal of Clinical Oncology, 2019, 37, 9037-9037.	0.8	2
173	Preclinical characterization and efficacy of 4R9, a novel immune checkpoint blockade targeting CEACAM1 for cancer therapy.. Journal of Clinical Oncology, 2019, 37, e14155-e14155.	0.8	0
174	A machine learning based prediction model of anti-PD-1 therapy response using noninvasive clinical information and blood markers of lung cancer patients.. Journal of Clinical Oncology, 2019, 37, e14138-e14138.	0.8	1
175	Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treatment Reviews, 2018, 65, 1-10.	3.4	225
176	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. Cancer Research, 2018, 78, 3350-3362.	0.4	42
177	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21.	0.9	21
178	Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. Nature Biomedical Engineering, 2018, 2, 239-253.	11.6	18
179	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. Lung Cancer, 2018, 119, 36-41.	0.9	7
180	Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head and Neck, 2018, 40, 55-62.	0.9	26

#	ARTICLE	IF	CITATIONS
181	A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 864-871.	0.7	18
182	Copy Number Abnormalities and Gene Fusions in Lung Cancer. , 2018, , 82-94.e4.		0
183	Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types. <i>Cancer Immunology Research</i> , 2018, 6, 87-97.	1.6	106
184	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.	13.9	3,530
185	Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. <i>Lung Cancer</i> , 2018, 115, 12-20.	0.9	131
186	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3290-3297.	0.8	515
187	A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy. <i>European Journal of Cancer</i> , 2018, 104, 104-107.	1.3	2
188	RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF- $\kappa$ B-mediated ERK reactivation. <i>Cell Death and Disease</i> , 2018, 9, 587.	2.7	23
189	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 122, 234-242.	0.9	22
190	Can We Prevent Resistance to Osimertinib? Combination or Sequential. <i>Journal of Thoracic Oncology</i> , 2018, 13, 877-879.	0.5	2
191	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1373-1382.	0.5	77
192	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-Front Mutations. <i>Cancer Discovery</i> , 2018, 8, 1227-1236.	7.7	321
193	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. <i>Lung Cancer</i> , 2018, 124, 168-178.	0.9	23
194	Allosteric Inhibitor TREA-0236 Containing Non-Hydrolysable Quinazoline-one for EGFR T790M/C797S Mutants Inhibition. <i>Bulletin of the Korean Chemical Society</i> , 2018, 39, 895-898.	1.0	15
195	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9043-9043.	0.8	45
196	Durvalumab in 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9058-9058.	0.8	3
197	Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) $\geq$ 1%: Open-label, phase 3 KEYNOTE-042 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA4-LBA4.	0.8	146
198	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 148-156.	0.4	15

#	ARTICLE	IF	CITATIONS
199	Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2018, 36, e18015-e18015.	0.8	0
200	Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer. Journal of Neuro-Oncology, 2017, 132, 333-340.	1.4	3
201	Treatment options for EGFR mutant NSCLC with CNS involvementâ€”Can patients BLOOM with the use of next generation EGFR TKIs?. Lung Cancer, 2017, 108, 29-37.	0.9	37
202	Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rho GTPase 1, and Ability to Induce Invasiveness of Gastric Cancer Cells. Gastroenterology, 2017, 153, 191-204.e16.	0.6	158
203	Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 873-880.	1.1	10
204	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer, 2017, 106, 76-82.	0.9	11
205	Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma. Apmis, 2017, 125, 974-984.	0.9	17
206	Structure-Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TREA069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment. Bulletin of the Korean Chemical Society, 2017, 38, 1353-1357.	1.0	6
207	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine, 2017, 5, 891-902.	5.2	92
208	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer, 2017, 112, 195-199.	0.9	9
209	Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lung Cancer, 2017, 113, 106-114.	0.9	48
210	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, 1357-1367.	0.5	144
211	Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer. Lung Cancer, 2017, 111, 79-83.	0.9	7
212	Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma. Oral Oncology, 2017, 75, 16-21.	0.8	21
213	Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK Positive Human Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 491-500.	0.5	21
214	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. Journal of Clinical Oncology, 2017, 35, 2613-2618.	0.8	260
215	A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget, 2017, 8, 15943-15951.	0.8	11
216	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. Journal of Clinical Oncology, 2017, 35, 2006-2006.	0.8	17

#	ARTICLE	IF	CITATIONS
217	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. Journal of Clinical Oncology, 2017, 35, 2020-2020.	0.8	63
218	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. Journal of Clinical Oncology, 2017, 35, 2069-2069.	0.8	12
219	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9036-9036.	0.8	10
220	Updated survival of patients (pts) with previously treated BRAF V600E mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.. Journal of Clinical Oncology, 2017, 35, 9075-9075.	0.8	37
221	Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.. Journal of Clinical Oncology, 2017, 35, 9536-9536.	0.8	18
222	Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. Oncotarget, 2017, 8, 65111-65122.	0.8	23
223	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization. Oncotarget, 2017, 8, 87234-87243.	0.8	17
224	Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study. Radiation Oncology Journal, 2017, 35, 153-162.	0.7	5
225	Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma. Cancer Research and Treatment, 2017, 49, 185-192.	1.3	16
226	Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective. Cancer Research and Treatment, 2017, 49, 168-177.	1.3	14
227	Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. Journal of Clinical Oncology, 2017, 35, 92-92.	0.8	0
228	Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M) Tj ETQqO O O rgBT /Overlock 10 Tf 50	0.8	0
229	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget, 2016, 7, 10547-10556.	0.8	52
230	Alteration status and prognostic value of MET in head and neck squamous cell carcinoma. Journal of Cancer, 2016, 7, 2197-2206.	1.2	20
231	Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Pharmacogenetics and Genomics, 2016, 26, 116-125.	0.7	11
232	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. Cancer, 2016, 122, 3024-3031.	2.0	72
233	Induction docetaxel and S followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma. Head and Neck, 2016, 38, E1653-9.	0.9	4
234	Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer, 2016, 102, 82-88.	0.9	46

#	ARTICLE	IF	CITATIONS
235	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. <i>Scientific Reports</i> , 2016, 6, 19552.	1.6	26
236	A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2016, 11, e55-e58.	0.5	70
237	ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. <i>Lung Cancer</i> , 2016, 95, 57-64.	0.9	7
238	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 822-835.	5.1	390
239	EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E Mutant NSCLC Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1627-1636.	1.9	8
240	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. <i>Scientific Reports</i> , 2016, 6, 36956.	1.6	196
241	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. <i>Lung Cancer</i> , 2016, 97, 73-80.	0.9	122
242	Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 122-129.	0.8	21
243	A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 539-548.	1.1	10
244	A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). <i>Lung Cancer</i> , 2016, 93, 1-8.	0.9	13
245	Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9002-9002.	0.8	59
246	Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9014-9014.	0.8	8
247	BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9055-9055.	0.8	27
248	Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. <i>Oncotarget</i> , 2016, 7, 24172-24178.	0.8	41
249	PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 30691-30701.	0.8	28
250	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016, 7, 36311-36320.	0.8	44
251	The Clinical Usefulness of <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 928-941.	1.3	10
252	Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20575-e20575.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.. Journal of Clinical Oncology, 2016, 34, 9081-9081.	0.8	1
254	Defining the immunologic phenotypes and their prognostic impacts on head and neck squamous cell cancer (HNSCC).. Journal of Clinical Oncology, 2016, 34, 6055-6055.	0.8	0
255	Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Medicine, 2015, 7, 98.	3.6	74
256	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer, 2015, 121, 2612-2617.	2.0	63
257	Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. Journal of Thoracic Oncology, 2015, 10, 1221-1228.	0.5	25
258	Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. Clinical Cancer Research, 2015, 21, 544-552.	3.2	56
259	The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. Lung Cancer, 2015, 88, 325-331.	0.9	8
260	An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. European Journal of Cancer, 2015, 51, 1588-1595.	1.3	42
261	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in <i>RET</i> -Rearranged Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2015, 14, 2238-2248.	1.9	19
262	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nature Medicine, 2015, 21, 560-562.	15.2	1,280
263	Reduced expression of E124 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells. Lung Cancer, 2015, 90, 175-181.	0.9	12
264	Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme. PLoS ONE, 2015, 10, e0137678.	1.1	6
265	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 2562-2572.	0.8	30
266	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 44971-44984.	0.8	13
267	Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements. PLoS ONE, 2014, 9, e103333.	1.1	68
268	A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant Activating EGFR Mutation and ROS1 Rearrangement. The Ewha Medical Journal, 2014, 37, 46.	0.1	0
269	Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer, 2014, 83, 389-395.	0.9	63
270	Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung Cancer, 2014, 84, 196-202.	0.9	53



#	ARTICLE	IF	CITATIONS
271	A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 665-671.	1.1	21
272	A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 229-243.	1.2	105
273	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1379-1388.	5.1	119
274	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 505-521.	1.4	97
275	Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers. <i>Genome Medicine</i> , 2014, 6, 18.	3.6	37
276	Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. <i>Lung Cancer</i> , 2014, 83, 374-382.	0.9	40
277	Tumor $MET$ expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2014, 5, 517-524.	0.8	5
278	NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8036-8036.	0.8	9
279	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8051-8051.	0.8	22
280	A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4083-4083.	0.8	0
281	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013, 21, 1751-1759.	1.0	38
282	Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. <i>Future Oncology</i> , 2013, 9, 377-386.	1.1	18
283	A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2013, 79, 270-275.	0.9	17
284	Personalized therapy on the horizon for squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2013, 80, 249-255.	0.9	60
285	Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 313-318.	0.9	11
286	Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 731-737.	0.8	154
287	Glycolysis Inhibition Sensitizes Non-Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2145-2156.	1.9	80
288	The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma. <i>Yonsei Medical Journal</i> , 2013, 54, 865.	0.9	18

#	ARTICLE	IF	CITATIONS
289	Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung. <i>Yonsei Medical Journal</i> , 2013, 54, 854.	0.9	14
290	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8027-8027.	0.8	22
291	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8028-8028.	0.8	28
292	Activation of IL-6R/JAK1/STAT3 Signaling Induces <i>De Novo</i> Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2254-2264.	1.9	179
293	Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2012, 7, 731-736.	0.5	20
294	Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 169-175.	0.6	21
295	High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 1760-1768.	3.2	60
296	Ei24-deficiency attenuates protein kinase C $\beta$ signaling and skin carcinogenesis in mice. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 1887-1896.	1.2	18
297	The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 539-546.	1.1	4
298	Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. <i>Cellular Immunology</i> , 2012, 278, 76-83.	1.4	75
299	EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI. <i>Yonsei Medical Journal</i> , 2012, 53, 1128.	0.9	23
300	Elevated Serum C-Reactive Protein as a Prognostic Marker in Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2012, 53, 111.	0.9	52
301	Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience. <i>Yonsei Medical Journal</i> , 2012, 53, 352.	0.9	60
302	The prognostic factors of resected non-small cell lung cancer with chest wall invasion. <i>World Journal of Surgical Oncology</i> , 2012, 10, 9.	0.8	36
303	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. <i>Cancer</i> , 2012, 118, 729-739.	2.0	132
304	A Case of Synchronous Squamous Cell Carcinoma in the Esophagus and Stomach. <i>Gut and Liver</i> , 2012, 6, 118-121.	1.4	5
305	Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18092-e18092.	0.8	0
306	Lung cancer in never smokers: Change of a mindset in the molecular era. <i>Lung Cancer</i> , 2011, 72, 9-15.	0.9	78

#	ARTICLE	IF	CITATIONS
307	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 685-693.	0.8	33
308	Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2011, 91, 344-348.	0.7	41
309	Multiple target loci assembly sequencing (mTAS). <i>Analytical Biochemistry</i> , 2011, 415, 218-220.	1.1	0
310	Weekly 5-Fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. <i>Head and Neck</i> , 2010, 32, 235-243.	0.9	8
311	Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1937-1944.	1.2	29
312	Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. <i>Cancer</i> , 2010, 116, 1336-1343.	2.0	99
313	The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2010, 51, 1.	0.9	4
314	Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients. <i>Oncology</i> , 2010, 79, 293-300.	0.9	15
315	Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. <i>Lung Cancer</i> , 2010, 70, 77-81.	0.9	14
316	Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. <i>Cancer Letters</i> , 2010, 296, 150-159.	3.2	53
317	Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 487-492.	0.8	74
318	Cancer in Patients on Chronic Dialysis in Korea. <i>Journal of Korean Medical Science</i> , 2009, 24, S95.	1.1	35
319	High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2426-2432.	3.2	85
320	Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1647-1654.	1.2	69
321	Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 27-32.	1.1	25
322	Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 106-110.	0.9	56
323	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1102-1110.	5.1	28
324	Complete Response of Recurrent Squamous Cell Carcinoma of the Lung: Dose the Dose Matter?. <i>Journal of Thoracic Oncology</i> , 2009, 4, 141-142.	0.5	0

#	ARTICLE	IF	CITATIONS
325	Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. <i>BMC Cancer</i> , 2008, 8, 8.	1.1	12
326	The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. <i>Lung Cancer</i> , 2008, 60, 393-400.	0.9	11
327	Phase II Study of Erlotinib in Advanced Non-Small-Cell Lung Cancer After Failure of Gefitinib. <i>Journal of Clinical Oncology</i> , 2007, 25, 2528-2533.	0.8	140
328	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007, 46, 547-549.	0.8	1
329	Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. <i>Journal of Surgical Oncology</i> , 2007, 95, 461-468.	0.8	89
330	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 75-81.	1.1	10
331	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 157-165.	1.1	13
332	Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 309-313.	1.1	11
333	Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. <i>Oncology Reports</i> , 2006, 15, 621-7.	1.2	6
334	Primary Idiopathic Chylopericardium Associated with Cervicomediastinal Cystic Hygroma. <i>Yonsei Medical Journal</i> , 2005, 46, 439.	0.9	19
335	A Pilot Study of Trans-Arterial Injection of <sup>166</sup> Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2005, 46, 799.	0.9	11
336	A Carcinoembryonic Antigen-Secreting Adenocarcinoma Arising in Tailgut Cyst : Clinical Implications of Carcinoembryonic Antigen. <i>Yonsei Medical Journal</i> , 2005, 46, 555.	0.9	26
337	Subacute Bacterial Endocarditis Associated with Upper Endoscopy. <i>Yonsei Medical Journal</i> , 2004, 45, 936.	0.9	9
338	Clinical and Echocardiographic Characteristics of Pericardial Effusion in Patients Who Underwent Echocardiographically Guided Pericardiocentesis: Yonsei Cardiovascular Center Experience, 1993-2003. <i>Yonsei Medical Journal</i> , 2004, 45, 462.	0.9	38
339	A Case of Lactic Acidosis Caused by Stavudine in an AIDS Patient. <i>Korean Journal of Internal Medicine</i> , 2004, 19, 66-69.	0.7	1
340	Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC. , 0, , .		0